MedImmune has signed an in-licensing pact with Amgen for AMG 108, a new monoclonal antibody targeting the IL-1 pathway.
Subscribe to our email newsletter
As per the terms of the agreement, Amgen has given AMG 108 development rights to MedImmune worldwide, outside Japan.
The tie up allows Amgen to get upfront payment, development-related milestone payments for multiple indications, and royalties upon sale of a commercial product.
MedImmune research and development executive vice president Bahija Jallal said that the recent data indicates the importance of the IL-1 pathway in a variety of inflammatory conditions, and AMG 108 represents a compelling opportunity to explore this antibody’s activity against various diseases for which patients need new treatment options.